SCHEMBL2039293

SCHEMBL2039293

Brc1csc2c1CCCC2

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.42
MAPT P10636 5/20 0.41
TP53 P04637 4/20 0.41
THRB P10828 1/20 0.41
ALDH1A1 P00352 5/20 0.41
LMNA P02545 2/20 0.41
GFER P55789 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SMN1; SMN2 Q16637 7/20 0.38
TSHR P16473 2/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 2/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.36
STAT3 P40763 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16297464 0.95
SCHEMBL13021599 0.75 HPGD (0.44) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL23840301 0.73 HPGD (0.44) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL24701727 0.73 HPGD (0.41) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL15920403 0.70 BPTF (0.41) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL18430366 0.69 ALDH1A1 (0.43) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL31564472 0.69 HPGD (0.38) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL15073114 0.69 HPGD (0.47) HPGDMAPTTP53THRBALDH1A1
SCHEMBL5786181 0.69 HPGD (0.41) HPGDMAPTTP53ALDH1A1LMNA
SCHEMBL1121587 0.69 HPGD (0.41) HPGDMAPTTP53ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034093-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2026-02-05 US disclosed
US-20240358675-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUMITOMO PHARMA AMERICA, INC. (US) 2024-10-31 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
CN-118165002-A Polycyclic compounds and methods of use thereof 桑诺维恩药品公司 2024-06-11 CN disclosed
EP-3252057-B1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2024-03-27 EP disclosed
US-20230159566-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING SAME SFC CO., LTD. (KR) 2023-05-25 US disclosed
US-20230159566-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING SAME SFC CO., LTD. (KR) 2023-05-25 US disclosed
EP-4137497-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING ELEMENT COMPRISING SAME SFC Co., Ltd. (KR) 2023-02-22 EP disclosed
US-20140256712-A1 Multicyclic Compounds and Methods of Use Thereof PSYCHOGENICS INC. (US) 2014-09-11 US disclosed
US-8710245-B2 Multicyclic compounds and methods of use thereof PSYCHOGENICS INC. (US) 2014-04-29 US disclosed
US-8710245-B2 Multicyclic compounds and methods of use thereof PSYCHOGENICS INC. (US) 2014-04-29 US disclosed
US-8710245-B2 Multicyclic compounds and methods of use thereof PSYCHOGENICS INC. (US) 2014-04-29 US disclosed
US-20130109677-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF PSYCHOGENICS INC. (US) 2013-05-02 US disclosed
US-20130109677-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF PSYCHOGENICS INC. (US) 2013-05-02 US disclosed
US-20130109677-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF PSYCHOGENICS INC. (US) 2013-05-02 US disclosed
EP-2507245-A2 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF Sunovion Pharmaceuticals Inc. (US) 2012-10-10 EP disclosed
WO-2011069063-A2 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed
WO-2011069063-A2 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159566-A1 NOVEL BORON COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING SAME CLTB, CD79B, CYBA HPGD 4312/4885MAPT 1077/4885TP53 3968/4885
US-20240358675-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF GRIN2C, NLN, COMT HPGD 757/4885MAPT 234/4885TP53 3095/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 HPGD 218/4885MAPT 2356/4885TP53 2515/4885
US-20140256712-A1 Multicyclic Compounds and Methods of Use Thereof GRIN2C, NLN, COMT HPGD 757/4885MAPT 234/4885TP53 3095/4885
US-20130109677-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF GRIN2C, NLN, COMT HPGD 757/4885MAPT 234/4885TP53 3095/4885
US-20260034093-A1 MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF SLC6A3, SLC6A11, SLC6A13 HPGD 2377/4885MAPT 156/4885TP53 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.